PMI-AD is a JPND funded collaboarative effort to map early innate immune activation and synapse loss in predementia Alzheimer´s disease. Inflammation and synapse loss are linked to premorbid genetic predispositions, and proteomic changes in cerebrospinal fluid and blood, and imaging changes, as seen e.g. with brain magnetic resonance techniques. Thus, PMI-AD aims are to profile each patient for these types of changes, as a starting point for precision therapies. 

The project is lead by Professor Tormod Fladby (Ahus, Norway) with partners in the Netherlands (Prof. Pieter J. Visser, Amsterdam UMC), Sweden (Prof. Kaj Blennow, University of Gothenburg & Prof .Bengt Winblad, Karolinska Institute), Denmark (Prof. Mads Nielsen, University of Copenhagen) and Slovenia (Prof. Milica Kramberger, University of Ljubljana) 

A main contributer to the PMI-AD project, is the Norwegian multicentre cohort "Dementia Disease Initiation", of which the Arctic University of Norway (UiT) and the University Hospital Of North-Norway (UNN) are part of. 

One of our PhD students in Tromsø, Stephanie Knudtzon, MD contributes to the PMI-AD project through her helse-nord funded project "Sex, inflammation and sex hormones in Alzheimer’s Disease progression: A gateway to precision medicine?"
Associate Prof. II, Bjørn-Eivind Kirsebom participates in various work-groups in PMI-AD for cerebrospinal fluid and blood-based biomarkers in early AD.